Innovative highly concentrated Omega-3 Specialized Nutrition Product

Informations projet

LIFEOMEGA

N° de convention de subvention: 755889

DOI

10.3030/755889

Projet clôturé

Date de signature de la CE 27 Février 2017

Date de début 1 Mars 2017

Date de fin 30 Novembre 2020

Financé au titre de

• SOCIETAL CHALLENGES - Food security, sustainable agriculture and forestry, marine, maritime and inland water research, and the bioeconomy

Coût total

€ 2 478 024,46

Contribution de l’UE

€ 1 712 046,88

Coordonné par

SOLUTEX GC SL
Spain

Periodic Reporting for period 4 - LIFEOMEGA (Innovative highly concentrated Omega-3 Specialized Nutrition Product)

Période du rapport: 2019-12-01 au 2020-11-30

Résumé du contexte et des objectifs généraux du projet

The objective of the project is the industrial and market development of a high concentrated Omega3 EPA nutritional
product addressed to improve the health of cancer patients.
LIFEOMEGA intends to provide faster recovery of cancer patients after chemo and radio therapies as follows:

1. The deficit of necessary level essential Omega3 EPA fatty acid by one efficient concentration and daily dosage (3g EPA per day)
2. Unique delivery form as an easy-to-ingest emulsion

The product of the project is protected by IP and constitutes a unique solution, not present in the market. Moreover, it is flavourized, and being an emulsion, it can be conveniently delivered into other liquids. These features make the product a breakthrough in the essential nutrition market, both in Europe and in the USA.
Cancer patients receiving radio/chemotherapy will benefit significantly from consumption of the emulsion. Faster recovery also means reduced length of hospital stay, and improved quality of life for cancer patients. The emulsion and its EPA concentration (3g/20ml) allow the consumption of higher concentrations of EPA than are currently available in the Omega3 market.

In conclusion, the emulsion is being commercialized worldwide and available to the malnourished cancer patient population while Solutex continues to test its effectiveness in specific groups of cancer patients.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

The work performed involved activities related to:
1. An optimized formulation.
2. Industrial scale-up.
3. Commercial agreement negotations.
4. Clinical trails initiation and management.

Solutex achieved:
a. A supply and license agreement.
b. Industrial capacity to fullfill emulsion supply.
c. Emulsion effectiveness data in healthy volunteers and cancer patients.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

The lifeOmega project delivered a unique emulsion of EPA for the foods for special medical purposes (FSMP) market.
The product has the potential to aid the recovery of the growing number of cancer patients worldwide.

capsules-vs-emulsion.jpg